# SECTION 5 - 510(k) Summary ELITech Clinical Systems GLUCOSE PAP SL reagent

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

The assigned 510(k) number is: K100525

# Submitter Address Phone number Fax number

SEPPIM S.A.S.   
Zone Industrielle, 61500 SEES, FRANCE + 33 (0)2 33 81 21 00   
+ 33 (0)2 33 28 77 51

# Contact

Valérie GOURDON (Email: v.gourdon@elitechgroup.com)

Date of Preparation

Monday, February 15th 2010

# Device names

# REAGENT :

# ELITech Clinical Systems GLUCOSE PAP SL Glucose, "GLUCoSE PAP SL"

Trade/proprietary Name:   
Common or Usual Name:   
Device Class   
Classification name   
Product code

Class II Glucose test system (Sec.862.1345) CGA - Glucose Oxidase, Glucose

# Predicate device

ABX PENTRA GLUCOSE PAP CP (K052007)

# Device description

The device for this submission is available as kit only. It consists of 1 reagent, "R."

Reagent R consists of Phosphate buffer (pH 7.4), Phenol, 4-Aminoantipyrine (4-AAP), Glucose oxidase (Aspergillus sp.), Peroxidase (horseradish) and sodium azide.

# Intended Use

ELITech Clinical 'Systems GLUCOSE PAP SL is intended for use with ELITech Clinical Systems ELICAL 2 and ELITech Clinical Systems ELITROL I and ELITROL II on Vital Scientific Selectra/Flexor analyzers for the quantitative in vitro diagnostic determination of glucose in human serum and plasma. It is not intended for use in Point of Care settings.

# Indication(s) for Use

ELITech Clinical Systems GLUCOSE PAP SL is intended to measure glucose in human serum and plasma. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma

# Comparison to Predicate device

<table><tr><td colspan="4"></td></tr><tr><td colspan="2">GLUCOSE PAP SL</td><td>ELITech Clinical Systems Device</td><td>Predicate device (ABX PENTRA GLUCOSE PAP CP)</td></tr><tr><td>Intended use</td><td>Intended for use with ELITech Clinical Systems ELICAL 2 and ELITech Clinical Systems ELI- TROL I and ELITROL II on Vital Scientific Selectra/Flexor analyz- ers for the quantitative in vitro diagnostic determination of glu- cose in human serum and plas-</td><td>in serum and plasma.</td><td>For in vitro diagnostic use in the quantitative determination of glucose</td></tr><tr><td>Indication(s) for Use</td><td>ma. It is not intended for use in Point of Care settings. Intended to measure glucose in human serum and plasma. Glu- cose measurements are used in the diagnosis and treatment of carbohydrate metabolism disor- ders including diabetes mellitus, neonatal hypoglycemia, and idio-</td><td>pathic hypoglycemia, and of pan-</td><td>Intended to measure glucose in hu- man serum and plasma. Glucose measurements are used in the diag- nosis and treatment of carbohydrate metabolism disorders including dia- betes mellitus, neonatal hypoglyce- mia, and idiopathic hypoglycemia, and of pancreatic islet cell carci-</td></tr><tr><td>Assay protocol</td><td>creatic islet cell carcinoma. Enzymatic method using glucose oxidase coupled with peroxidase (Trinder method).</td><td>noma.</td><td>Enzymatic method using glucose oxidase coupled with peroxidase (Trinder method).</td></tr><tr><td>Composition</td><td>Reagent R: Phosphate buffer; pH 7.4 13.8 mmol/L; Phenol 4-Aminoantipyrine Glucose oxidase Peroxidase</td><td>Reagent: 10 mmol/L ; Phenol 0.3 mmol/L; 4-Aminoantipyrine ≥ 10 000 U/L ; Glucose oxidase ≥ 700 U/L; Peroxidase</td><td>Phosphate buffer; pH 7.4 13.8 mmol/L; 10 mmol/L; 0.3 mmol/L ; ≥ 10 000 U/L ; 700 U/L;</td></tr><tr><td>Appearance of reagent</td><td>Sodium azide Liquid form, ready to use</td><td>&lt;0.1%; Same</td><td>Sodium azide &lt;0.1%;</td></tr><tr><td>Sample type</td><td>Serum Plasma</td><td>Serum Plasma</td><td></td></tr><tr><td>Reagent storage</td><td>Store at 2-8 °C and protected from light. The reagent is stable until the expiry date stated on the label.</td><td>stored at 2-8 C.</td><td>Reagents, in unopened cassette, are stable up to expiry date on the label if</td></tr><tr><td>Expected values</td><td>Serum, plasma 74 - 106 mg/dL</td><td>Serum, plasma 74 - 106 mg/dL</td><td></td></tr><tr><td>Instrument</td><td>SELECTRA JUNIOR</td><td>ABX PENTRA 400</td><td></td></tr><tr><td>Measuring range</td><td>20.0 to 400.0 mg/dL Rerun: 800.0 mg/dL</td><td>1.8 to 432 mg/dL</td><td>Automatic post-dilution: 1296 mg/dL</td></tr><tr><td>Detection</td><td>0.5 mg/dL</td><td>1.8 mg/dL</td><td></td></tr><tr><td>Precision</td><td>Within run Level 36.5 mg/dL CV=1.6% Level 107.4 mg/dLCV=1.4% Level 301.5 mg/dLCV=1.0%</td><td>Within run Level 89.36 mg/dL Level Level 111.47 mg/dL Level 296.22 mg/dL</td><td>CV=0.41% Level 230.53 mg/dL CV=0.40% 42.76 mg/dL CV=0.62% CV=0.30%</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ELITech Clinical Systems DeviceGLUCOSE PAP SL</td><td rowspan=1 colspan=1>Predicate device(ABX PENTRA GLUCOSE PAP CP)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>TotalLevel36.5 mg/dL CV=2.9%Level107.4 mg/dL CV=2.5%Level301.5 mg/dL CV=2.1%</td><td rowspan=1 colspan=1>TotalLevel 90.20 mg/dL  CV=1.23%Level235.44 mg/dLCV=1.12%Level107.18 mg/dLCV=1.44%Level298.97 mg/dLCV=1.05%</td></tr><tr><td rowspan=1 colspan=1>Method comparison</td><td rowspan=1 colspan=1>y=0.953 x + 3.05 mg/dL2= 0.997range: 17.9 to 417.2 mg/dL</td><td rowspan=1 colspan=1>y= 0.98 x + 0.72 mg/dL2= 0.9974</td></tr><tr><td rowspan=1 colspan=1>Limitations</td><td rowspan=1 colspan=1>Hemoglobin: Positive bias from250 mg/dL on low human serum.No significant interference up to500 mg/dL on medium human se-rum.Triglycerides: Positive bias from814 mg/dL.Unconjugated bilirubin: Positivebias from 15 mg/dL on low humanserum. Negative bias from 18mg/dL on medium human serum.Conjugated bilirubin: Negativebias from 8 mg/dL on low humanserum and from 18 mg/dL on me-dium human serum.Ascorbic acid: Negative bias from2 mg/dl on low human serum andfrom 12 mg/dL on medium humanserum.Uric acid: Negative bias from 19mg/dL on low human serum. Nosignificant interference up to 24mg/dL on medium human serum.Methyldopa: Negative bias from0.9 mg/dL on low human serum. Nosignificant interference up to 1mg/dL on medium human serum.</td><td rowspan=1 colspan=1>Hemoglobin: No significant influ-ence is observed up to 460 mg/dL.Triglycerides: No significant influ-ence is observed up to 613 mg/dL.Total bilirubin: No significant influ-ence is observed up to 8.19 mg/dL.Direct bilirubin: No significant influ-ence is observed up to 5.63 mg/dL.</td></tr><tr><td rowspan=1 colspan=1>Calibration Frequency</td><td rowspan=1 colspan=1>28 days</td><td rowspan=1 colspan=1>11 days</td></tr><tr><td rowspan=1 colspan=1>On board stability</td><td rowspan=1 colspan=1>refrigerated area : 28 days</td><td rowspan=1 colspan=1>refrigerated area: 83 days</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Recommended calibration material(not included):ELITech Clinical Systems Elical 2</td><td rowspan=1 colspan=1>Recommended calibration material(not included):ABX Pentra Multical</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Recommended quality control ma-terial (not included):ELITech Clinical Systems Elitrol 1(Normal control)ELITech Clinical Systems Elitrol II(Pathologic control)</td><td rowspan=1 colspan=1>Recommended quality control mate-rial (not included):ABX Pentra N Control(Normal control)ABX Pentra P Control (Pathologiccontrol</td></tr></table>

# Conclusion

The performance data and other information demonstrate that the safety and effectiveness of this device versus the predicate device is not compromised, and that it met all acceptance criteria, demonstrating that the device is substantially equivalent to its predicate device.

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

The assigned 510(k) number is: K100525

Submitter Address Phone number Fax number

SEPPIM S.A.S.   
Zone Industrielle, 61500 SEES, FRANCE + 33 (0)2 33 81 21 00   
$^ +$ 33 (0)2 33 28 77 51

# Contact

Valérie GOURDON (Email: v.gourdon@elitechgroup.com)

Date of Preparation Monday, February 15th 2010

# Device names

# REAGENT :

Trade/proprietary Name: ELITech Clinical Systems ELICAL 2

Common or Usual Name:   
Device Class   
Classification name   
Product code

Calibrator, multi-analyte mixture, "ELICAL Class II Calibrator (21 CFR 862.1150) JIX- Calibrator, multi-analyte mixture

# Predicate device

# Roche Diagnostics Calibrator for Automated Systems (C.f.a.s) (K033501)

# Device description

ELITech Clinical Systems ELICAL 2 is a lyophilized calibrator based on human serum containing constituents to ensure optimal calibration.

ELICAL 2 is prepared exclusively from the blood of donors tested individually and found to be negative for HbsAg and to antibodies to HCV and HIV according to FDA-approved methods or methods in compliance with the European Directive 98/79/EC, Annex II, List A.

# Intended Use

ELITech Clinical Systems ELICAL 2 is a multi-parametric calibrator for in vitro diagnostic use in the calibration of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

# Comparison to Predicate device

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ELITech Clinical Systems Device(ELICAL 2)</td><td rowspan=1 colspan=1>Predicate device(Roche Calibrator f.a.s.)</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>ELITech Clinical Systems ELICAL2 is a multi-parametric calibratorfor in vitro diagnostic use in thecalibration of quantitative ELITechClinical Systems methods on theVital Scientific Selectra JuniorAnalyzer and the Vital ScientificFlexor Junior Analyzer.</td><td rowspan=1 colspan=1>For in vitro diagnostic use in thecalibration of quantitative Rochemethods on Roche clinical chemis-try analysers as specified in thevalue sheets.</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized calibrator based onhuman serum with constituentsadded as required to obtain desiredcomponents levels</td><td rowspan=1 colspan=1>Lyophilized calibrator based onhuman serum with constituentsadded as required to obtain desiredcomponents levels</td></tr><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>Single level</td><td rowspan=1 colspan=1>Single level</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Carefully open the vial, avoiding theloss of lyophilate, and pipette inexactly 3 mL of distilled/deionizedwater. Carefully close the vial anddissolve the contents completely byoccasional gentle swirling within 30minutes avoiding the formation offoam.</td><td rowspan=1 colspan=1>Carefully open one bottle, avoidingthe loss of lyophilate, and pipette inexactly 3 mL of distilled/deionizedwater. Carefully close the bottle anddissolve the contents completely byoccasional gentle swirling within 30minutes. Avoid the formation offoam.</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Traceability information is given inthe value sheet included in the box.</td><td rowspan=1 colspan=1>Traceability of the target value isgiven in the respective instructionfor use of the system reagents.</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Lyophilized:To store at 2-8°C and protectedfrom light until the expiry dateAfter reconstitution, the stabilitiesare :- 8 hours between 15-25 °C.- 2 days between 2-8 C.- 4 weeks between -25 and -15 C(when frozen once)</td><td rowspan=1 colspan=1>Lyophilized:Stable at 2-8°C up to expirationdate.After reconstitution, the stabilities*are :- 8 hours at 15-25 C.- 2 days at 2-8 °C.- 4 weeks at (-25)-(-15) °C (whenfrozen once)*Exception for bilirubin total &amp; directas noted in package insert</td></tr></table>

Elical 2 assigned values are the following ones:   

<table><tr><td colspan="1" rowspan="1">Components</td><td colspan="1" rowspan="1">Under review</td><td colspan="1" rowspan="1">Included in thissubmission</td><td colspan="1" rowspan="1">Cleared</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">AST-GOT</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">K093883</td></tr><tr><td colspan="1" rowspan="1">Glucose</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Phosphorus</td><td colspan="1" rowspan="1">K100263</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Total Protein</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">X</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Urea</td><td colspan="1" rowspan="1">K100263</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">BUN</td><td colspan="1" rowspan="1">K100263</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Uric acid</td><td colspan="1" rowspan="1">K100263</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Cholesterol</td><td colspan="1" rowspan="1">K102993</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Triglycerides</td><td colspan="1" rowspan="1">K102993</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Y</td></tr></table>

# Conclusion

The performance data and other information demonstrate that the safety and effectiveness of this device versus the predicate device is not compromised, and that it met all acceptance criteria, demonstrating that the device is substantially equivalent to its respective predicate device.

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

The assigned 510(k) number is:_ K100525

# Submitter Address Phone number Fax number

SEPPIM S.A.S.   
Zone Industrielle, 61500 SEES, FRANCE + 33 (0)2 33 81 21 00   
+ 33 (0)2 33 28 77 51

# Contact

Valérie GOURDON (Email: v.gourdon@elitechgroup.com)

Date of Preparation Monday, February 15th 2010

# Device names

# ELITech Clinical Systems ELITROL I and ELITROL II

CONTROLS:   
Trade/proprietary Name:   
Common or Usual Name:   
Device Class   
Classification name   
Multi-analyte controls — all kinds, "ELITROL I" "ELITROL II'   
Class 1   
Quality control material (assayed and unassayed). (21 CFR   
862.1660)   
JJX- Multi-analyte controls - all kinds

Product code

# Predicate device

Roche Diagnostics Precinorm U (K041227) Roche Diagnostics Precipath U (K041227)

# Device description

ELITech Clinical Systems ELITROL I and ELITROL II are two level quality control products consisting of lyophilized human serum containing constituents at desired levels.

Elitrol I and Elitrol Il are prepared exclusively from the blood of donors tested individually and found to be negative for HbsAg and to antibodies to HCV and HIV according to FDA-approved methods or methods in compliance with the European Directive 98/79/EC, Annex II, List A.

# Intended Use

ELITech Clinical Systems ELITROL I is a multi-parametric control serum for in vitro diagnostic use in accuracy control of quantitative ELlTech Clinical Systems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

ELITech Clinical Systems ELITROL II is a multi-parametric control serum for in vitro diagnostic use in accuracy control of quantitative ELITech Clinical Sys-. tems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

# Comparison to Predicate device

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ELITech Clinical Systems DeviceELITROL I/ ELITROL II</td><td rowspan=1 colspan=1>Predicate DeviceRoche Precinorm U / Precipath U</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>ELITech Clinical Systems ELITROLI is a multi-parametric control serumfor in vitro diagnostic use in accu-racy control of quantitative ELITechClinical Systems methods on theVital Scientific Selectra Junior Ana-lyzer and the Vital Scientific FlexorJunior Analyzer.ELITech Clinical Systems ELITROLII is a multi-parametric control se-rum for in vitro diagnostic use inaccuracy control of quantitativeELITech Clinical Systems methodson the Vital Scientific Selectra Jun-ior Analyzer and the Vital ScientificFlexor Junior Analyzer.</td><td rowspan=1 colspan=1>For in vitro diagnostic use in qualitycontrol by monitoring accuracy andprecision for the quantitative meth-ods as specified in the value sheet</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized human sera with con-stituents added as required to ob-tain desired components levels</td><td rowspan=1 colspan=1>Lyophilized human sera with con-stituents added as required to ob-tain desired components levels</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Two levels</td><td rowspan=1 colspan=1>Two levels</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Carefully open the vial, avoiding theloss of lyophilate, and pipette inexactly 5 mL of distilled/deionizedwater. Carefully close the vial anddissolve the contents completely byoccasional gentle swirling within 30minutes avoiding the formation offoam.</td><td rowspan=1 colspan=1>Carefully open the bottle, avoidingthe loss of lyophilate, and pipette inexactly 5 mL of distilled/deionizedwater. Carefully close the bottle anddissolve the contents completely byoccasional gentle swirling within 30minutes. Avoid the formation offoam.</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Lyophilized:To store at 2-8°C and protectedfrom light until the expiry dateAfter reconstitution, the stabilitiesare :- 12 hours between 15-25 °C.- 5 days between 2-8 C.- 4 weeks between -25 and -15 °C(when frozen once)</td><td rowspan=1 colspan=1>Lyophilized:Stable at 2-8°C up to expirationdate.After reconstitution, the stabilities*are :- 12 hours at 15-25 °C.- 5 days at 2-8 C.- 4 weeks at (-25)-(-15) °C (whenfrozen once)*Exception for bilirubin total &amp; directas noted in package insert</td></tr></table>

Elitrol I & Elitrol Il assigned values are the following ones:   

<table><tr><td rowspan=1 colspan=1>Components</td><td rowspan=1 colspan=1>Under review</td><td rowspan=1 colspan=1>Included in thissubmission</td><td rowspan=1 colspan=1>Cleared</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>AST-GOT</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>K093883</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Phosphorus</td><td rowspan=1 colspan=1>K100263</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

<table><tr><td rowspan=1 colspan=1>Total Protein</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>X</td></tr><tr><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>K100263</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>BUN</td><td rowspan=1 colspan=1>K100263</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Uric acid</td><td rowspan=1 colspan=1>K100263</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>K102993</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>K102993</td><td rowspan=1 colspan=1></td></tr></table>

# Conclusion

The performance data and other information demonstrate that the safety and effectiveness of these devices versus the predicate devices are not compromised, and that it met all acceptance criteria, demonstrating that the device is substantially equivalent to its respective predicate device.

Seppim S.A.S.   
c/o Debra K. Hutson   
ELITechGroup Epoch Biosciences $2 1 7 2 0 2 3 ^ { \mathrm { r d } }$ Dr. SE, Suite 150   
Bothell, Washington 98021

Re: k100525 Trade Name: ELITech Clinical Systems Glucose PAP SL, ELITech Clinical Systems ELICAL 2, ELITech Clinical Systems ELITROL 1 and ELITROL 2 Regulation Number: 21 CFR $\ S 8 6 2 . 1 3 4 5$ Regulation Name: Glucose test system Regulatory Class: Class II Product Codes: CGA, JIX, JJX Dated: December 13, 2010 Received: December 15, 2010

Dear Ms. Hutson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

Ir evi  cas ebovin cass Spelonocass II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 89meiviportiotmldvirelavvt ( CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and. 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

GC.

Coubthey Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use Form

510(k) Number (if known): _K100525

Device Name: _ ELITech Clinical Systems GLUCOSE PAP SL

Indications for Use:

ELITech Clinical Systems GLUCOSE PAP SL is intended for use with ELITech Clinical Systems ELICAL 2 and ELITech Clinical Systems ELITROL I and ELITROL l for the quantitative in vitro diagnostic determination of glucose in human serum and plasma on Vital Scientific Selectra/Flexor analyzers. It is not intended for use in Point of Care settings.

Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/aa9ad9356b0052c58f9e5cc19490da9d79519340f509031dd1db121d6921af91.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K/00525

# Indications for Use Form

510(k) Number (if known): _K100525

Device Name: __ELITech Clinical Systems ELICAL 2_

Indications for Use:

ELITech Clinical Systems ELICAL 2 is a multi-parametric calibrator for in vitro diagnostic use in the calibration of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/99caa753b02fef2eb1b47fba19e66ba1f2a26bef6f92edac0eb8357ba316bbde.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

# Indications for Use Form

510(k) Number (if known): _K100525

Device Name: _ELITech Clinical Systems ELITROL 1 and ELITROL 2_

Indications for Use:

ELITech Clinical Systems ELITROL I is a multi-parametric control serum for in vitro diagnostic use in accuracy control of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior Analyzer and the Vital Scientific Flexor Junior Analyzer.

ELITech Clinical Systems ELITROL I is a multi-parametric control serum for in vitro diagnostic use in accuracy control of quantitative ELITech Clinical Systems methods on the Vital Scientific Selectra Junior analyzer and the Vital Scientific Flexor Junior analyzers.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/645edfd14c637d2a27c169eb3cd9909def59044be0ad06c017e9478090200c2a.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K100525